The Current Ratio as of November 2024 (TTM) for Cytokinetics, Incorporated (CYTK) is 10.39

According to Cytokinetics, Incorporated’s latest financial reports and current stock price. The company's current Current Ratio is 10.39. This represents a change of 34.42% compared to the average of 7.73 of the last 4 quarters.

Cytokinetics, Incorporated (CYTK) Historical Current Ratio (quarterly & annually)

How has CYTK Current Ratio performed in the past?

The mean historical Current Ratio of Cytokinetics, Incorporated over the last ten years is 7.88. The current 10.39 Current Ratio has changed 13.08% with respect to the historical average. Over the past ten years (40 quarters), CYTK's Current Ratio was at its highest in in the December 2020 quarter at 15.20. The Current Ratio was at its lowest in in the September 2015 quarter at 3.33.

Cytokinetics, Incorporated (CYTK) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cytokinetics, Incorporated Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cytokinetics, Incorporated (CYTK) Average Current Ratio

How has CYTK Current Ratio performed in the past?

The current Current Ratio of Cytokinetics, Incorporated (CYTK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cytokinetics, Incorporated (CYTK) Current Ratio vs. Peers

How is CYTK’s Current Ratio compared to its peers?

Cytokinetics, Incorporated’s Current Ratio is less than DICE Therapeutics, Inc. (25.88), less than Edgewise Therapeutics, Inc. (30.24), less than Karuna Therapeutics, Inc. (19.31), less than Dyne Therapeutics, Inc. (26.63), greater than Stoke Therapeutics, Inc. (6.67), less than Pliant Therapeutics, Inc. (14.47), less than Revolution Medicines, Inc. (15.42), less than Relay Therapeutics, Inc. (15.64), greater than Black Diamond Therapeutics, Inc. (6.87), greater than Arvinas, Inc. (4.17), less than Terns Pharmaceuticals, Inc. (21.02), greater than Amylyx Pharmaceuticals, Inc. (4.66), less than Acumen Pharmaceuticals, Inc. (17.37), greater than Inozyme Pharma, Inc. (9.84), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Blueprint Medicines Corporation (3.32),

Build a custom stock screener for Cytokinetics, Incorporated (CYTK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cytokinetics, Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cytokinetics, Incorporated (CYTK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cytokinetics, Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.